mTOR-FABP4 signal is activated in brain arteriovenous malformations in humans
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR-FABP4 signal is activated in brain arteriovenous malformations in humans
Authors
Keywords
-
Journal
JOURNAL OF MOLECULAR MEDICINE-JMM
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-07-25
DOI
10.1007/s00109-022-02237-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evidence for endothelial‐to‐mesenchymal transition in human brain arteriovenous malformations
- (2020) Lorelei D. Shoemaker et al. Clinical and Translational Medicine
- Neurovascular inflammation in the pathogenesis of brain arteriovenous malformations
- (2020) S. Krithika et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Inhibition of mTOR Alleviates Early Brain Injury After Subarachnoid Hemorrhage Via Relieving Excessive Mitochondrial Fission
- (2019) Yuchen Li et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
- Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models
- (2019) Santiago Ruiz et al. JOURNAL OF CLINICAL INVESTIGATION
- Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain
- (2018) Sergey I. Nikolaev et al. NEW ENGLAND JOURNAL OF MEDICINE
- High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations
- (2018) Tao Hong et al. BRAIN
- The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis
- (2018) Hannah V. Woodcock et al. Nature Communications
- Management of Complex Arteriovenous Malformations Using a Novel Combination Therapeutic Algorithm
- (2018) Malcolm Pyles Chelliah et al. JAMA Dermatology
- Fatty acid binding protein 4 expression in cerebral vascular malformations: implications for vascular remodelling
- (2015) Sule Cataltepe et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Brain arteriovenous malformations
- (2015) Michael T. Lawton et al. Nature Reviews Disease Primers
- Low Concentration of Rapamycin Inhibits Hemangioma Endothelial Cell Proliferation, Migration, and Vascular Tumor Formation in Mice
- (2014) Ningning Zheng et al. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
- Fatty Acid-binding Protein 4, a Point of Convergence for Angiogenic and Metabolic Signaling Pathways in Endothelial Cells
- (2014) Ulrike Harjes et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity
- (2014) Jun Kawasaki et al. JOURNAL OF CLINICAL INVESTIGATION
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- Sturge–Weber Syndrome and Port-Wine Stains Caused by Somatic Mutation in GNAQ
- (2013) Matthew D. Shirley et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin
- (2013) S. A. Kang et al. SCIENCE
- Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway
- (2012) Harun Elmasri et al. ANGIOGENESIS
- The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors
- (2011) Anne Dormond-Meuwly et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Computational Tool for Quantitative Analysis of Vascular Networks
- (2011) Enrique Zudaire et al. PLoS One
- Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells
- (2009) Harun Elmasri et al. FASEB JOURNAL
- Direct control of mitochondrial function by mTOR
- (2009) Arvind Ramanathan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ten-Year Detection Rate of Brain Arteriovenous Malformations in a Large, Multiethnic, Defined Population
- (2009) Rodney A. Gabriel et al. STROKE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started